CEO John Leonard highlighted that "with up to 3 years of patient follow-up, we have yet to see any waning of effect in serum kallikrein or TTR levels in the extended follow-up of our Phase I and II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results